TrialBlood advances2025

Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.

Michael J Mauro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.